We sought to identify factors influencing dose maintenance of intracavernous (IC) injection among patients with ED following radical prostatectomy. A total of 93 patients underwent prostatectomy and received IC treatment for ED, including PGE1 single therapy (n ¼ 53) and triple therapy (n ¼ 40). In the PGE1-only group, the maintenance dosage was significantly correlated with preoperative sexual function and nerve sparing (NS) (Po0.05). For example, the maintenance dose among patients with no, unilateral and bilateral NS was 10.8 ± 6.6 lg (0.54 ± 0.33 ml), 10.8 ± 3.8 lg (0.54 ± 0.19 ml) and 6.4 ± 4.6 lg (0.32 ± 0.23 ml), respectively. In terms of preoperative sexual function, the maintenance dose among non-ED versus ED patients was 0.38±0.25 ml (7.6±5.0 lg) and 0.59±0.31 ml (11.8±6.2 lg), respectively. No significant correlation was observed between the maintenance dose and NS or preoperative sexual function among the triple-therapy patients or between the maintenance dose and age, body mass index, systemic diseases and initiation of ED treatment among all patients (P40.05). Thus, maintenance dose of PGE1 therapy could be partly determined by NS status and prior ED of patients.
Introduction
Prostate cancer is the most common non-cutaneous malignancy among US men and the second leading cause of cancer death. For several decades, radical prostatectomy (RP) has been the standard treatment for organ-confined prostate cancer. Prevention and management of ED following RP remains a major concern for the practicing urologist. Men with RPinduced ED and those in whom oral therapy has failed or is contraindicated often require intracavernous (IC) injections. [1] [2] [3] [4] [5] IC injections were previously reported as an excellent option for maintaining erectile function among nerve sparing (NS) patients in whom oral therapy has failed. In this prior study, no difference in the efficacy of IC was observed between the type of RP performed (bilateral NS, unilateral NS and non-NS) or between the regimen options (PGE1 single, triple therapy). IC injections have been shown to provide excellent long-term efficacy and compliance in up to 70% of patients with ED after RP. 6 Ismail et al. 7 have studied the factors that influence dose initiation and maintenance in the treatment of ED with IC alprostadil therapy (PGE1, 20 mg ml -1 ) and found the average maintenance dose to vary with the etiology of ED. Specifically, the central neurogenic group was more responsive to PGE1 therapy than men with vascular etiologies. The authors concluded that dosing considerations vary widely in the clinical setting, and their determination is greatly facilitated if primary and associated causes of ED are considered. To the effect, age, obesity, diabetes and hypertension are the mostimportant risk factors in relation to preoperative sexual function. 8 Thus, in the present study, we sought to determine whether the maintenance dose of IC injections in postprostatectomy patients is affected by preoperative erectile function, body mass index (BMI), age, systemic diseases and initiation of ED treatment.
Materials and methods
Baseline and follow-up data from patients using IC injection for ED following RP were retrospectively collected after Institutional Review Board approval. Patients had either failed to respond to oral therapy or PDE5 inhibitor administration was contraindicated. Patients were stratified according to the type of NS RP (bilateral NS, unilateral NS and non-NS), operation record and the type of regimen (PGE1 single, triple therapy). Patients who were lost to follow-up are excluded from the analysis. We conducted a retrospective chart review of 93 of our patients who underwent prostatectomy by different surgeons in urology clinics in Cleveland and were subsequently treated with IC injection.
The IC regimens used in this study were as follows: triple therapy (5.88 mg ml -1 PGE1 þ 0.59 mg ml -1 phentolamine þ 17.65 mg ml -1 papaverine), and PGE1 only (20 mg ml -1 ). Patient training was conducted by an experienced nurse practitioner during 2-3 office visits and consisted of selection of an appropriate vasoactive agent, dose titration, patient education regarding sterile technique and hemostasis and partner education. In some cases, the spouse or sexual partner performed the injections if the patient was unable or unwilling to do so. Patients were routinely instructed to change injection sites to prevent corporeal fibrosis and to change their drug regimen (dose and type of IC solution) to ensure effectiveness. A maintained dose was set at the lowest dosage allowing the patient to experience enough penile rigidity to allow for successful intercourse.
International Index for Erectile Function-5 (IIEF-5) and self-estimate of erectile rigidity (complete flaccid: 0; full rigidity: 10) were assessed at baseline and post-RP. ED severity was classified into five categories by IIEF-5, including 22-25-none, and 17-21-mild, 12-16-mild to moderate, 8-11-moderate and 5-7-severe ED. Additional patient data included age, BMI, treatment effect, duration of erection following penile injections, dose titration and dose maintained. The correlation of maintained dosage with the multiple factors, such as age, preoperative erectile function, BMI, diabetes and hypertension was examined in the different therapy groups. The Statistic Package for the Social Sciences (SPSS, Chicago, IL, USA) was used to analyze the data. Specifically, means were calculated, and statistically significant variance between factors was identified using multiple regressions.
Statistical significance was determined at a P-value of o0.05.
Results
A total of 93 patients who underwent prostatectomy using IC treatment for ED had been receiving regular follow-up. Among those, 53 patients received PGE1 single and 40 patients received triple therapy. Prior to therapy initiation, patients had experienced ED for a mean of 9 months (range: 6-12 months) after surgery.
The patient profiles of the PGE1-only and the tripletherapy groups are provided in Table 1 . Briefly, the average age of the PGE1 therapy group was 59.3 ± 6.3 years. Of the 53 patients, 24 had a bilateral NS procedure, 11 a unilateral NS procedure and 11 a non-NS procedure. Additionally, 18 patients had hypertension and 1 patient diabetes. According to the IIEF-5, 10 patients had ED (7 patients had mild ED and 3 patients had mild-to-moderate ED). The average maintenance dosage of PGE1-only therapy was 8.2±5.4 mg (0.42±0.27 ml). The mean value of selfestimate of erectile rigidity (complete flaccid: 0; full rigidity: 10) was 1.9 (range: 0-6) pre-IC treatment, and 7.9 (range: 5-10) post-IC treatment. The maintenance dose had significant correlation between NS (Po0.01) and preoperative sexual function (P:0.03). In terms of NS, as portrayed in Table 2 , patients with no NS versus unilateral and bilateral NS had a maintenance dose of 10.8 ± 6.6 mg (0.54±0.33 ml), 10.8±3.8 mg (0.54±0.19 ml) and 6.4±4.6 mg (0.32±0.23 ml), respectively. Finally, among patients without ED at baseline, the maintenance dose was 7.6±5.0 mg (0.38±0.25 ml) but 11.8±6.2 mg (0.59±0.31 ml) among patients with baseline ED.
The improved value of self-estimate erectile rigidity between pre-IC treatment and post-IC treatment was significant with the maintenance dose Intracavernous injection after prostatectomy F-P Chuang et al (Po0.05). The maintenance dose had no significant correlation between age, BMI and hypertension or DM.
In the triple-therapy group of 40 patients, mean age was 58.3 ± 5.6 years ( Table 1) . Of the 40 patients, 20 patients had a bilateral NS procedure, 10 had a unilateral NS procedure and 10 had a non-NS procedure, while 17 patients had hypertension and 6 had diabetes. According to the IIEF-5, 6 patients had mild ED, 1 mild-to-moderate ED and 3 moderate ED. The average maintenance dosage of low-dose triple therapy was 0.42 ± 0.25 ml. The mean value of self-estimate erectile rigidity (complete flaccid: 0; full rigidity: 10) was 1.6 (range: 0-5) pre-IC treatment, and 8.5 (range: 7-10) post-IC treatment. The improved value of self-estimate erectile rigidity between pre-IC treatment and post-IC treatment was significant with the maintenance dose (Po0.05). The maintenance dose had no significant correlation with NS (Table 2) , preoperative sexual function, age, BMI, hypertension and DM (P40.05).
Discussion
RP is the most common treatment for localized prostate cancer, with over 60 000 men undergoing the procedure every year in the United States. [1] [2] [3] 9 Despite recent improvements in performing RP that have led to a considerable decrease in the treatmentassociated sequelae, ED still represents a major problem. 4 The main postulated cause of ED in these patients is the temporary cavernous nerve damage, resulting in penile hypoxia, smooth muscle apoptosis, fibrosis and veno-occlusive dysfunction. While the surgical technique and experience remain the dominant variables in outcome, other factors including the patient's age, preoperative sexual function, psychological adjustment to a cancer diagnosis, the nature of operation (that is NS, unilateral or bilateral) and coexisting medical diseases (such as diabetes or hypertension) can also affect postoperative ED. In addition, more preoperative variables such as the stage of disease, preservation of the neurovascular bundles, urinary incontinence and adjuvant treatments may also have an influence of postoperative ED risk. 1, 2, 5, 9, 10 Various treatments for ED after RP, such as vacuum constriction devices, intraurethral and intracorporal alprostadil, PDE5 inhibitors and prothesis, might serve to facilitate recovery of erectile function. 11, 12 Since the introduction of oral PDE5 inhibitors, oral therapy has become the first-line treatment option for ED, irrespective of etiology. The efficacy of sildenafil citrate after RP correlated with the degree of neurovascular bundle preservation, preoperative erectile function status, age and interval before starting treatment. The report by Raina et al. 13 showed that 57% patients responded to the sildenafil citrate, but within the responding patients, 76% were in the bilateral NS group, 53.5% in the unilateral NS group and 14.2% in the non-NS group. While the use of an oral agent (PDE5 inhibitors) is optimal, the consideration to introduce this option in postprostatectomy patients depends on the presence of 1 or 2 neurovascular bundles.
14 Nevertheless, patients who have undergone a non-NS procedure and those in whom oral therapy has failed or is contraindicated require other options such as IC injections. [15] [16] [17] PGE1 (alprostadil) induces erections by directly stimulating the production of cyclic AMP within the smooth muscle cell and therefore does not require a functioning nerve to induce SM relaxation. The fact that PGE1 has a direct vasodilatory effect on smooth muscle in the penis is the basis for its efficacy in the treatment of non-NS or NS post-RP ED. 9, 18 However, for the patients in whom PGE1 therapy failed or who have significant penile pain with PGE1, the selfinjection therapy using a mixture of vasoactive substances (papaverine, phentolamine and prostaglandin E1) is an alternative treatment, which has been proven to be at least as effective as alprostadil alone, and has a much lower incidence of painful erection. The high success rate (94.6-100%) suggests that the triple-drug combination represents a good option for the treatment of male patients with ED after RP with very mild side effects that resolve spontaneously. 4, 19 The dose response to prostaglandin based on NS has never been reported. This study is the first time a dose calibration has correlated to NS status for a single agent (PGE1). In the PGE1 single therapy group, the maintenance dose was significantly correlated to NS and preoperative sexual function. However, no significant correlation was shown in the triple-therapy group. For the patients who are non-responders to PGE1 therapy, the possibility of using a mixture of vasoactive substances (vasoactive Intracavernous injection after prostatectomy F-P Chuang et al cocktail) still exists. The rationale of polypharmacotherapy is the synergistic action of vasoactive drugs, which differ in mechanism and site of action. For instance, PGE1 acts via adenyl cyclase and guanylate cyclase activation, papaverine exerts a non-selective inhibitory effect on cyclic nucleotide phosphodiesterasis and phentolamine is a competitive a-adrenoceptor antagonist. The final result is enhanced corporeal smooth muscle relaxation and, consequently, a better erection. Otherwise, papaverine and phentolamine are characterized by chemical stability when blended together or with PGE1. Papaverine and/or phentolamine increase the naturally occurring degradation of PGE1 in physiological solution. [20] [21] [22] It is interesting that in prior reports men with central neurogenic ED fare better on injections than men with vascular ED. 7 It is implied that PgE1 works primarily through vascular mechanisms and induction of cAMP. In these data set, men with more severe neurogenic ED (nerve resection during prostatectomy) required higher dose PgE1 monotherapy. It is implied that nerve integrity remains important for the activity of PgE1 or that nerve activity works synergistically with PgE1. It is possible that the triple action of trimix affects the same downstream vascular changes that are normally driven by the cavernous nerves, hence reducing the difference in dosage required for men with or without nerve preservation.
Among elderly patients, the development of hypoxia-induced tissue damage and fibrosis of the corpora cavernosa are the major cause of ED after RP. 23 Reviews of the literatures have shown that age, obesity and urinary tract symptoms are the mostimportant factors attributed to the occurrence of ED. 1, 5, [8] [9] [10] 12, 23 The appropriate dose of PGE1 used for ED treatment depends on the etiology. For instance, men with peripheral vascular causes for ED require higher IC dosing than men with neurogenic causes. 7, 8 In our study, the data indicate that men with bilateral NS fair better with injections than men with unilateral or non-NS approaches that are associated with fibrosis and vascular impairment (diabetes, hypertension). Therefore, nerve integrity seems to have a significant role in the efficacy of PGE1 treatment. On the other hand, the maintenance dose for ED after RP had no significant correlation with age, BMI and systemic disease. Nevertheless, the improved value of self-estimate erectile rigidity between pre-IC treatment and post-IC treatment was significant with the maintenance dose.
If patients need to use PGE1, we have to consider the relation between dosage and patients' special conditions (condition of NS and preoperation erectile function). Patients need to receive different titration dosage depending on the individual's condition. If patients have to use triple regimen (5.88 mg ml -1 PGE1 þ 0.59 mg ml -1 phentolamine þ 17.65 mg ml -1 papaverine), the titration dose could begin from 0.4 to 0.45 ml and the condition of NS may be of little influence.
The current study had a number of limitations that warrant mention. First, inclusion of questions on ability to achieve and maintain erection to completion of intercourse (such as SEP2 and SEP3) would have been of utility in understanding treatment efficacy. Second, despite the knowledge that triple therapy has relatively less complications, not everyone used triple therapy due to relative high cost and unavailability in each clinic. Third, we did not have enough patients with diabetes to perform appropriate analyses.
Conclusion
In our study, in the PGE1-only therapy group, the maintenance dose was significantly correlated with NS and preoperative sexual function; findings not observed in the triple-therapy group. Thus, nerve integrity appears to have a significant role in the efficacy of PGE1 regime. The maintenance dose was not associated with age, BMI, the presence of hypertension or duration of erection following penile injection. Factors related to the IC dose for treatments of ED patients after RP remain to be fully elucidated.
